Information Provided By:
Fly News Breaks for February 21, 2018
ESPR
Feb 21, 2018 | 09:10 EDT
Needham analyst Chad Messer raised his price target on Esperion to $94 and kept his Strong Buy rating. Messer notes that regulatory uncertainty for the company is in the past, while the phase 3 readouts on its Bempedoic Acid products starting next month could disclose further progress toward a "blockbuster opportunity". The analyst says that the readouts are "significantly de-risked" given the lack of any safety signals to date.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.